Thymalin vs Thymosin Beta-4
How Thymalin and Thymosin Beta-4 compare — what each is, how strong the human evidence is for each, doses reported in research, the key risks, and 2026 US legal status. No universal winner.
Thymalin and Thymosin Beta-4 come up together when people are weighing similar options. Here's the honest side-by-side: what each is, how strong the human evidence is for each, the doses reported in research, the risks, and where each stands with the FDA as of 2026. There's no universal winner — scroll to the by-goal picks for which one fits which goal.
Thymalin vs Thymosin Beta-4, point by point
Every dimension side by side — the honest differences, not a scoreboard.
| Dimension | Thymalin | Thymosin Beta-4 |
|---|---|---|
| What it is | Thymus-derived polypeptide preparation (an immunomodulator; chemical databases also index it under the thymulin/nonathymulin nonapeptide) | Naturally occurring 43-amino-acid actin-sequestering peptide (thymosin β4) |
| Class / category | Longevity / mitochondrial | Healing / recovery |
| Evidence tier | Human (controlled) · Mixed | Animal-only · Unclear · none in humans |
| Studied / approved for | Immune restoration / secondary immunodeficiency; Healthy aging / geroprotection | Dry eye disease / ocular surface repair (topical); Neurotrophic keratitis (topical); Cardiac repair after heart attack; Dermal wound healing (pressure & venous ulcers); Soft-tissue and musculoskeletal recovery |
| US regulatory status (2026) | research use only (as of Jul 2026) | research use only (as of Jul 2026) |
| Doses reported in research | No established study doses | No established study doses |
| Registered trials (ClinicalTrials.gov) | 0 | 18 |
| Banned in sport (WADA) | No | Yes — on the WADA prohibited list |
| Key risks | Thymalin has an unusually long clinical-use history — decades as a registered immunomodulator in Russia — where it was generally described as well tolerated. That track record is reassuring but not the same as modern long-term safety data, which is thin by Western standards. Because thymalin is extracted from animal thymus tissue rather than chemically synthesized, it also carries the theoretical concerns of any tissue-derived biologic: allergic or immune reactions and contamination if purification is poor. In the US it is sold as an unregulated research chemical, so purity, dose accuracy and sterility vary by vendor. | Thymosin beta-4 was generally well tolerated in the small completed human trials (topical eye drops and early systemic studies), with no major safety signal reported — but those trials were small and short, and there is no long-term human safety data for the muscle-recovery use people inject it for. The most-discussed theoretical concern is the flip side of its mechanism: a peptide that drives cell migration and new blood-vessel growth raises the reasonable, unproven question of whether it could feed something you would not want to grow. |
- Evidence tier: A tier reflects how human the evidence is, not a promise the compound works.
Thymalin vs Thymosin Beta-4: the two molecules
The 2D chemical structures, straight from PubChem — a quick way to see how similar (or not) the two actually are.
Which one fits which goal?
There's no universal winner here — the honest answer depends on what you're after. These picks are framed by goal, and each says why.
If you want the option with more human evidence behind it
Leans toward Thymalin
Thymalin's evidence sits at human (controlled), a more human tier than Thymosin Beta-4's animal-only. That reflects how the data was gathered, not a guarantee it works.
References
- 1.Thymalin — indexed research (PubMed, National Library of Medicine)
- 2.Thymalin — human-tagged clinical research (PubMed filter)
- 3.Thymalin compound record (PubChem CID 3085284)
- 4.Thymalin — registered clinical studies (ClinicalTrials.gov)
- 5.FDA — drug approval information
- 6.Thymosin beta-4 — indexed research (PubMed, National Library of Medicine)